A Multi-Centre, Double-Blind, Parallel Group Study to Evaluate the Efficacy of SEREVENT 50mg BID Versus Placebo BID all Administered via the Multi Dose Powder Inhaler (DISKUS/ACCUHALER) in Terms of Symptoms in the Treatment of Patients With Chronic Obstructive Pulmonary Disease, Trial ID SLGF53

A Multi-Centre, Double-Blind, Parallel Group Study to Evaluate the Efficacy of SEREVENT 50mg BID Versus Placebo BID all Administered via the Multi Dose Powder Inhaler (DISKUS/ACCUHALER) in Terms of Symptoms in the Treatment of Patients With Chronic Obstructive Pulmonary Disease, Trial ID SLGF53 | GSK